Bivalirudin Excretion and Elimination
Bivalirudin is eliminated predominantly through enzymatic proteolytic cleavage (80%), with only 20% excreted unchanged via renal glomerular filtration, tubular secretion, and tubular reabsorption. 1, 2
Primary Elimination Pathways
Enzymatic metabolism accounts for the majority of bivalirudin clearance:
- Approximately 80% undergoes proteolytic cleavage by thrombin and other proteases, breaking down the drug intracellularly into constituent amino acids 1, 3, 4
- This enzymatic degradation occurs independently of renal or hepatic function 1
Renal excretion represents the minor pathway:
- Only 20% is excreted unchanged through the kidneys 1, 2, 3
- Renal elimination involves glomerular filtration, tubular secretion in the proximal convoluted tubule, and tubular reabsorption in the distal convoluted tubule 5
- Approximately 25% of bivalirudin can be cleared by hemodialysis 1, 2
Impact of Renal Impairment on Clearance
Despite predominantly non-renal elimination, renal dysfunction significantly affects bivalirudin pharmacokinetics:
Normal to Mild Renal Impairment (CrCl ≥60 mL/min)
- Total body clearance remains similar between normal renal function (3.4–4.58 mL/min/kg) and mild impairment 2, 3, 5
- Elimination half-life stays approximately 25 minutes 1, 6, 2
- No dose adjustment required 7
Moderate Renal Impairment (CrCl 30–59 mL/min)
- Clearance reduced by 20–21% 2, 3, 5
- Half-life prolonged to approximately 34 minutes 2
- Infusion rate should be reduced to 1.4 mg/kg/hour during procedures or 0.08–0.1 mg/kg/hour for medical treatment 7, 1, 8
Severe Renal Impairment (CrCl <30 mL/min)
- Clearance reduced by 24–68% depending on severity 3, 5
- Half-life extended to 57 minutes 2
- Infusion rate should be reduced to 1.0 mg/kg/hour during procedures or 0.03–0.05 mg/kg/hour for medical treatment 7, 8
- Bivalirudin is contraindicated in severe renal failure (CrCl <30 mL/min) according to some guidelines 1
Dialysis-Dependent Patients
- Clearance reduced by 70–77% 2, 5
- Half-life prolonged to 3.5 hours 2
- Hemodialysis removes approximately 25% of circulating bivalirudin 1, 2
- Starting doses of 0.03–0.05 mg/kg/hour are recommended, with careful aPTT monitoring 9, 8
Clinical Implications
The predominantly enzymatic elimination provides theoretical advantages but requires vigilance in renal impairment:
- Coagulation times (ACT, aPTT) return to baseline approximately 1 hour after discontinuation in patients with normal renal function 2
- This recovery time is significantly prolonged in renal impairment, increasing bleeding risk 5, 8
- Major bleeding incidence correlates directly with declining renal function, though bivalirudin still demonstrates lower bleeding rates than heparin across all renal function categories 5
- Dosing requirements correlate strongly with creatinine clearance (r² = 0.37, p<0.0001) 8